세계의 병리학용 AI 시장 : 제공 제품별, 신경망별, 기능별, 이용 사례별, 최종 사용자별, 지역별 - 예측(-2029년)

The global AI in Pathology market is expected to reach USD 169.8 million by 2029 from USD 82.8 million in 2024 at a high CAGR of 15.4% during the forecast period. AI in pathology refers to the healthcare industry's sector which comprises of development, deployment, and utilization of Artificial Intelligence (AI) designed for pathology applications specifically. Clinical data, genomic information, and disease progression can be analysed by using these AI models. These AI models assist in personalized treatment planning, identifying high-risk patients, and optimizing healthcare resource allocation. The AI helps and assists pathologists in extracting relevant information and analyzing images with the use of advanced AI algorithms, computer vision, and machine learning.

"The drug discovery segment accounted for the largest share in 2023, by use case."

In 2023, the drug discovery segment held the largest share of the AI in pathology market. The major factor behind this is the high demand for efficient and cost-effective drugs, as AI in pathology helps in accelerating the drug discovery process by automating the data analytics and identifying potential drug faster. In addition, the advancements in high throughput screenings imaging technologies and utilization of AI in toxicology testing for illicit drugs also act as a driving force for this market. Furthermore, the reduced time and costs play a very vital role as traditional methods are very time consuming and expensive as well, the introduction of AI in pathology helps in streamlining the process by enabling faster insights and decision making. Which in tun makes the process more efficient and cost effective, these all factors combined act as a catalyst for the growth of this market.

"Pharmaceutical and biopharmaceutical companies is the fastest growing end-user segment in the AI in pathology market."

The pharmaceutical and biopharmaceutical companies segment is projected to witness the highest growth rate during the forecast period. The growing collaboration between pharmaceutical companies and AI providers fuels rapid adoption of AI, also the companies are heavily investing in AI tools to stay competitive in drug development and innovation. As AI helps in fast tracking and streamlining the processes for drug discovery by analysing large datasets, identifying patterns in tissue samples, and predicting treatment responses, which reduces the time consumption and makes it cost effective, leading to faster innovations. The biopharmaceutical companies rely on AI-based digital pathology for majorly development of individualized medicine, as AI powered pathology aids the development of personalised medicine by providing detailed insights into individual portfolio.

"North America accounted for the largest share in 2023, in AI in pathology market."

In 2023, the North American region held the largest market share in the AI in pathology market due to several factors. The first and foremost being the high adoption of AI technology and strong investment in research and development driving the market growth. For instance, companies like Koninklijke Philips N.V. in 2023, invested nearly USD 895 million in R&D for diagnosis and treatment. On the other hand, the advanced healthcare infrastructre plays a very vital role in this market as there's a need of high tech machinery such as advanced microscopes and scanners. Morover, the large patient pool and data availability contributes in creating a large database, which can be further used to train the AI for greater accuracy and efficiency. This increasing focus on technoology, patient safety, and quality improvement, combined with technological advancements in medical devices, continues to drive the adoption of AI in pathology market in North America.

The break-down of primary participants is as mentioned below:

• By Company Type - Tier 1: 55%, Tier 2: 25%, and Tier 3: 20%
• By Designation - C-level: 50%, Director-level: 30%, and Others: 20%
• By Region - North America: 40%, Europe: 35%, Asia Pacific: 20%, RoW: 5%

Key Players in the AI in pathology Market

The key players functioning in the AI in pathology market include Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US), Akoya Biosciences, Inc. (US), Aiforia Technologies Plc (Finland), Indica Labs Inc. (US), OptraScan (US), Ibex Medical Analytics Ltd. (Israel), Mindpeak GmbH (Germany), Tribun Health (France), Techcyte, Inc. (US), Deep Bio Inc. (Korea), Lumea Inc. (US), Visiopharm (Denmark), aetherAI (Taiwan), Aiosyn (Netherlands), Paige AI, Inc. (US), Proscia Inc. (US), PathAI, Inc. (US), Tempus Labs, Inc. (US), Konfoong Biotech International Co., Ltd. (China), DoMore Diagnostics AS (Norway), Verily Life Sciences, LLC (US), deepPath (US), and 4D Path Inc (US).

Research Coverage:

The report analyses the AI in pathology market. It aims to estimate the market size and future growth potential of various market segments based on by offerings, neural networks, use-case, end-user, by functions and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

• Analysis of key drivers (Rising strategic collaborations among market players, integration of AI in multiplex imaging, Rising cases of misdiagnoses, AI-augmented telepathology broadening access to specialized pathology services, and technological advancements in deep learning), restraints (High cost of digital pathology systems, the scarcity of AI expertise and unclear regulatory guidelines for medical software, and lack of interoperability with legacy systems), opportunities (Growing demand for personalized medicine, integration of multi-omics data, and predictive analytics for disease Progression) challenges (Lack of sufficient data to train AI algorithms, data privacy, and ethical concerns, interpretability of AI models) influencing the growth of the AI in pathology market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the AI in pathology market.
• Market Development: Comprehensive information on the lucrative emerging markets, offering, neural networks, functions, use-case, end-user, and region.
• Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the AI in pathology market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the AI in pathology market like Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 MARKET STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 STUDY ASSUMPTIONS
• 2.5 RESEARCH LIMITATIONS
  • 2.5.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.5.2 SCOPE-RELATED LIMITATIONS
• 2.6 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 AI IN PATHOLOGY MARKET OVERVIEW
• 4.2 AI IN PATHOLOGY MARKET: REGIONAL MIX
• 4.3 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER & COUNTRY
• 4.4 GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Development of CNNs and advanced AI models
    • 5.2.1.2 Integration of AI into multiplex imaging
    • 5.2.1.3 Increasing cases of misdiagnoses in patients
    • 5.2.1.4 Benefits of AI-augmented telepathology
    • 5.2.1.5 Advancements in deep learning & image processing
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of digital pathology systems
    • 5.2.2.2 Limited AI expertise and varied regulatory guidelines for medical software
    • 5.2.2.3 Inadequate interoperability issues with legacy systems
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing demand for personalized medicine
    • 5.2.3.2 Integration of multi-omics data
    • 5.2.3.3 Predictive analytics for disease progression
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Insufficient data for AI algorithms
    • 5.2.4.2 Data privacy & ethical concerns
    • 5.2.4.3 Challenges associated with interpretability of AI models
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 INDUSTRY TRENDS
  • 5.4.1 EVOLUTION OF AI IN PATHOLOGY
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 TECHNOLOGY ANALYSIS
  • 5.7.1 KEY TECHNOLOGIES
    • 5.7.1.1 Machine learning and artificial intelligence
    • 5.7.1.2 Computer vision
  • 5.7.2 COMPLEMENTARY TECHNOLOGIES
    • 5.7.2.1 Cloud computing
  • 5.7.3 ADJACENT TECHNOLOGIES
    • 5.7.3.1 Telepathology
• 5.8 REGULATORY ANALYSIS
  • 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8.2 REGULATORY LANDSCAPE
    • 5.8.2.1 North America
      • 5.8.2.1.1 US
      • 5.8.2.1.2 Canada
    • 5.8.2.2 Europe
    • 5.8.2.3 Asia Pacific
      • 5.8.2.3.1 Japan
      • 5.8.2.3.2 China
• 5.9 PRICING ANALYSIS
  • 5.9.1 INDICATIVE PRICING ANALYSIS, BY OFFERING
  • 5.9.2 AVERAGE SELLING PRICE TREND, BY REGION
• 5.10 PORTER'S FIVE FORCES ANALYSIS
  • 5.10.1 THREAT OF NEW ENTRANTS
  • 5.10.2 THREAT OF SUBSTITUTES
  • 5.10.3 BARGAINING POWER OF SUPPLIERS
  • 5.10.4 BARGAINING POWER OF BUYERS
  • 5.10.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.11 PATENT ANALYSIS
  • 5.11.1 PATENT PUBLICATION TRENDS FOR AI IN PATHOLOGY SOLUTIONS
  • 5.11.2 JURISDICTION & TOP APPLICANT ANALYSIS
• 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 BUYING CRITERIA
• 5.13 END-USER ANALYSIS
  • 5.13.1 UNMET NEEDS OF END USERS
  • 5.13.2 END-USER EXPECTATIONS
• 5.14 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.15 CASE STUDY ANALYSIS
  • 5.15.1 CASE STUDY 1: PATHAI USES PYTORCH TO IMPROVE PATIENT OUTCOMES WITH AI-POWERED PATHOLOGY
  • 5.15.2 CASE STUDY 2: COMBATING CERVICAL CANCER WITH AI
• 5.16 INVESTMENT & FUNDING SCENARIO
• 5.17 AI IN PATHOLOGY MARKET: BUSINESS MODELS
• 5.18 IMPACT OF AI/GEN AI ON AI IN PATHOLOGY MARKET
  • 5.18.1 KEY USE CASES
  • 5.18.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION
    • 5.18.2.1 Case Study: Accelerated biomarker discovery and clinical trial optimization
  • 5.18.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    • 5.18.3.1 Drug discovery & development market
    • 5.18.3.2 Medical imaging & diagnostics market
  • 5.18.4 USERS READINESS AND IMPACT ASSESSMENT
    • 5.18.4.1 User readiness
      • 5.18.4.1.1 Pharmaceutical companies
      • 5.18.4.1.2 Biopharmaceutical companies
    • 5.18.4.2 Impact assessment
      • 5.18.4.2.1 User A: Pharmaceutical companies
        • 5.18.4.2.1.1 Implementation
        • 5.18.4.2.1.2 Impact
      • 5.18.4.2.2 User B: Biopharmaceutical companies
        • 5.18.4.2.2.1 Implementation
        • 5.18.4.2.2.2 Impact
• 5.19 TRADE ANALYSIS
  • 5.19.1 IMPORT DATA
  • 5.19.2 EXPORT DATA

6 AI IN PATHOLOGY MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 END-TO-END SOLUTIONS
  • 6.2.1 INCREASING DEMAND FOR INTEGRATED WORKFLOWS IN HEALTHCARE MODELS TO DRIVE MARKET
• 6.3 NICHE POINT SOLUTIONS
  • 6.3.1 GROWING FOCUS ON PRECISION MEDICINE AND TARGETED THERAPY RESEARCH TO PROPEL MARKET
• 6.4 TECHNOLOGY
  • 6.4.1 RISING NEED FOR ADVANCED DATA MANAGEMENT SOLUTIONS TO FUEL UPTAKE
• 6.5 HARDWARE
• 6.6 MICROSCOPES
  • 6.6.1 AUTOMATED ANALYSIS OF TISSUE SAMPLES FOR EFFECTIVE CONCLUSIONS TO FUEL UPTAKE
• 6.7 SCANNERS
  • 6.7.1 IMPROVEMENTS IN IMAGE QUALITY AND PRECISION DIAGNOSTICS TO BOOST DEMAND
• 6.8 STORAGE SYSTEMS
  • 6.8.1 ABILITY TO PROVIDE STRUCTURED MODELS OF HIGH-RESOLUTION IMAGES TO SUPPORT MARKET GROWTH

7 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK

• 7.1 INTRODUCTION
• 7.2 CONVOLUTIONAL NEURAL NETWORKS (CNNS)
  • 7.2.1 ABILITY TO PROVIDE HIGH-QUALITY IMAGE RECOGNITION AND OBJECTION DETECTION TO PROPEL MARKET
• 7.3 GENERATIVE ADVERSARIAL NETWORKS (GANS)
  • 7.3.1 DESIGNED FOR GENERATION OF ACCURATE SYNTHETIC PATHOLOGY IMAGES TO DRIVE MARKET
• 7.4 RECURRENT NEURAL NETWORKS (RNNS)
  • 7.4.1 ANALYSIS OF SEQUENTIAL DATA AND TIME-DEPENDENT PATTERNS TO FUEL UPTAKE
• 7.5 OTHER NEURAL NETWORKS

8 AI IN PATHOLOGY MARKET, BY FUNCTION

• 8.1 INTRODUCTION
• 8.2 IMAGE ANALYSIS
  • 8.2.1 DETECTION OF CELLULAR ANOMALIES AND DISEASE MARKERS TO FUEL UPTAKE
• 8.3 DIAGNOSTICS
  • 8.3.1 RAPID PROCESSION OF AUTOMATED SAMPLES TO DRIVE MARKET
• 8.4 WORKFLOW MANAGEMENT
  • 8.4.1 OPTIMIZATION OF LAB RESOURCES FOR HIGH-THROUGHPUT RESULTS TO FUEL UPTAKE
• 8.5 DATA MANAGEMENT
  • 8.5.1 ADVANCEMENTS IN DATA INTEGRATION & PROCESSING TO BOOST DEMAND
• 8.6 PREDICTIVE ANALYTICS
  • 8.6.1 GROWING FOCUS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET
• 8.7 CDSS
  • 8.7.1 PROVISION OF REAL-TIME INSIGHTS TO FUEL MARKET
• 8.8 AUTOMATED REPORT GENERATION
  • 8.8.1 INCREASING DEMAND FOR QUALITY CONTROL TO DRIVE MARKET
• 8.9 QUALITY ASSURANCE TOOLS
  • 8.9.1 RISING REGULATORY DEMANDS TO ACCELERATE DEMAND FOR QUALITY ASSURANCE TOOLS

9 AI IN PATHOLOGY MARKET, BY USE CASE

• 9.1 INTRODUCTION
• 9.2 DRUG DISCOVERY
  • 9.2.1 TARGET IDENTIFICATION & SELECTION
    • 9.2.1.1 Analysis of molecular & histological data for biomarker discovery to fuel market
  • 9.2.2 TARGET VALIDATION
    • 9.2.2.1 Increasing demand for precision medicine to drive market
  • 9.2.3 HIT IDENTIFICATION & PRIORITIZATION
    • 9.2.3.1 Growing requirement for rapid analysis and cost efficiency to fuel uptake
  • 9.2.4 HIT-TO-LEAD IDENTIFICATION
    • 9.2.4.1 Advancements in ML to support market growth
  • 9.2.5 LEAD OPTIMIZATION
    • 9.2.5.1 Growing focus on therapeutic efficacy to propel market
  • 9.2.6 CANDIDATE SELECTION & VALIDATION
    • 9.2.6.1 Critical requirement for regulatory approvals to drive market
• 9.3 DISEASE DIAGNOSIS & PROGNOSIS
  • 9.3.1 INCREASING INCIDENCE OF CHRONIC DISEASES TO FUEL MARKET
• 9.4 CLINICAL WORKFLOW
  • 9.4.1 STRUCTURED AUTOMATION OF EXTENSIVE VOLUME DATA TO DRIVE MARKET
• 9.5 TRAINING & EDUCATION
  • 9.5.1 UTILIZATION OF DIGITAL PATHOLOGY SYSTEMS IN ACADEMIC INSTITUTES TO SUPPORT MARKET GROWTH

10 AI IN PATHOLOGY MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
  • 10.2.1 GROWING FOCUS ON TOXICOLOGY TESTING TO PROPEL MARKET
• 10.3 HOSPITALS & REFERENCE LABORATORIES
  • 10.3.1 INCREASING UPTAKE OF INFECTIOUS DISEASE DIAGNOSIS TO DRIVE MARKET
• 10.4 ACADEMIC & RESEARCH INSTITUTES
  • 10.4.1 INCREASING INVESTMENTS IN LIFE SCIENCES RESEARCH TO SUPPORT MARKET GROWTH

11 AI IN PATHOLOGY MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 High healthcare expenditure and improvements in cloud computing platforms to propel market
  • 11.2.3 CANADA
    • 11.2.3.1 Increasing adoption of deep learning for advanced healthcare diagnostics to drive market
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 UK
    • 11.3.2.1 Increasing focus on drug discovery & development to boost demand
  • 11.3.3 GERMANY
    • 11.3.3.1 Availability of funding for AI initiatives to fuel uptake
  • 11.3.4 FRANCE
    • 11.3.4.1 Increasing adoption of big data in healthcare computing to fuel uptake
  • 11.3.5 ITALY
    • 11.3.5.1 Digital transformation and innovation in healthcare to support market growth
  • 11.3.6 SPAIN
    • 11.3.6.1 Workforce shortages to fuel market
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Increasing incidence of infectious & chronic diseases to fuel uptake
  • 11.4.3 JAPAN
    • 11.4.3.1 Advanced healthcare infrastructure to propel market
  • 11.4.4 INDIA
    • 11.4.4.1 Growing focus on healthcare digitization to boost demand
  • 11.4.5 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Strategic investments for AI adoption to support market growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Growth in pharmaceutical R&D to drive market
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Increasing investments in expansion of technological expertise to support market growth
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN PATHOLOGY MARKET
• 12.3 REVENUE ANALYSIS, 2019-2023
• 12.4 MARKET SHARE ANALYSIS, 2023
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Offering footprint
    • 12.5.5.3 Use-case footprint
    • 12.5.5.4 End-user footprint
    • 12.5.5.5 Region footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS /SMES, 2023
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 COMPANY VALUATION
  • 12.7.2 FINANCIAL METRICS
  • 12.7.3 BRAND/SOFTWARE COMPARISON ANALYSIS
• 12.8 COMPETITIVE SCENARIO
  • 12.8.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
  • 12.8.2 DEALS
  • 12.8.3 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 KONINKLIJKE PHILIPS N.V.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products/Services offered
    • 13.1.1.3 MnM view
      • 13.1.1.3.1 Key strengths
      • 13.1.1.3.2 Strategic choices
      • 13.1.1.3.3 Weaknesses & competitive threats
  • 13.1.2 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products/Services offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product/Service launches
      • 13.1.2.3.2 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 HOLOGIC, INC.
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products/Services offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product/Service approvals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 AKOYA BIOSCIENCES, INC.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products/Services offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 AIFORIA TECHNOLOGIES PLC
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products/Services offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Deals
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses & competitive threats
  • 13.1.6 INDICA LABS INC.
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products/Services offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product/Service launches & approvals
      • 13.1.6.3.2 Deals
      • 13.1.6.3.3 Expansions
  • 13.1.7 OPTRASCAN
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products/Services offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Other developments
  • 13.1.8 IBEX MEDICAL ANALYTICS LTD.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products/Services offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product/Service launches & approvals
      • 13.1.8.3.2 Deals
  • 13.1.9 MINDPEAK GMBH
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products/Services offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product/Service approvals
      • 13.1.9.3.2 Deals
      • 13.1.9.3.3 Other developments
  • 13.1.10 TRIBUN HEALTH
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products/Services offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Deals
  • 13.1.11 TECHCYTE, INC.
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products/services offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product/Service launches
      • 13.1.11.3.2 Deals
      • 13.1.11.3.3 Other developments
  • 13.1.12 DEEP BIO INC.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products/Services offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Deals
  • 13.1.13 LUMEA INC.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products/Services offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Deals
  • 13.1.14 VISIOPHARM
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products/Services offered
      • 13.1.14.2.1 Recent developments
      • 13.1.14.2.2 Product/Service launches
      • 13.1.14.2.3 Expansions
  • 13.1.15 AETHERAI
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products/Services offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Deals
  • 13.1.16 AIOSYN
    • 13.1.16.1 Business overview
    • 13.1.16.2 Product/Services offered
      • 13.1.16.2.1 Product/Service launches
    • 13.1.16.3 Recent developments
      • 13.1.16.3.1 Deals
    • 13.1.16.4 Recent developments
      • 13.1.16.4.1 Other developments
  • 13.1.17 PAIGE AI, INC.
    • 13.1.17.1 Business overview
    • 13.1.17.2 Products/Services offered
    • 13.1.17.3 Recent developments
      • 13.1.17.3.1 Product/Service launches & approvals
      • 13.1.17.3.2 Deals
      • 13.1.17.3.3 Other developments
  • 13.1.18 PROSCIA, INC.
    • 13.1.18.1 Business overview
    • 13.1.18.2 Products/Services offered
    • 13.1.18.3 Recent developments
      • 13.1.18.3.1 Product/Service launches & enhancements
      • 13.1.18.3.2 Deals
      • 13.1.18.3.3 Other developments
  • 13.1.19 PATHAI, INC.
    • 13.1.19.1 Business overview
    • 13.1.19.2 Products/Services offered
    • 13.1.19.3 Recent developments
      • 13.1.19.3.1 Product/Service launches & approvals
      • 13.1.19.3.2 Deals
  • 13.1.20 TEMPUS LABS, INC.
    • 13.1.20.1 Business overview
    • 13.1.20.2 Products/Services offered
    • 13.1.20.3 Recent developments
      • 13.1.20.3.1 Product/Service launches
• 13.2 OTHER PLAYERS
  • 13.2.1 KONFOONG BIOINFORMATION TECH CO., LTD.
  • 13.2.2 DOMORE DIAGNOSTICS AS
  • 13.2.3 VERILY LIFE SCIENCES, LLC
  • 13.2.4 DEEPPATH
  • 13.2.5 4D PATH INC.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS